If youre in a regulated field, we recommend discussing this with your provider our clinical team at THE RE/ CLINIC can help guide you
According to the financial reports by Novo Nordisk, the business revenue of GLP-1 RAs has reached 34,653 million Danish krone (DKK) in the first quarter of 2023 ( The FDA Adverse Event Reporting System (FAERS) is a robust pharmacovigilance database that contains real-world data on AE reporting ( Methods Data sources FAERS is an openly accessible pharmacovigilance database documenting AEs, medication errors, and product quality complaints reported spontaneously by people of diverse occupations worldwide ( Data extraction In order to acquire AE reports data treated with GLP-1 RAs, we identified the AEs of GLP-1 RAs in the DRUG files using the generic and brand names of the FDA-approved GLP-1 RAs, specifically exenatide (BYETTA, BYDUREON), liraglutide (VICTOZA, SAXENDA), lixisenatide (ADLYXIN, SOLIQUA), dulaglutide (TRULICITY), semaglutide (OZEMPIC, RYBELSUS, WEGOVY), and tirzepatide (MOUNJARO)
Heres the tricky parttheres no public dashboard telling us exactly how many Wyomingites are filling GLP1 prescriptions
Balancing desired benefits and potential risks, including those affecting mental health, remains essential
Persistent nausea lasting more than 48 hours after each injection
&srotate=0)
